US20070049747A1 - Process for the production of 3-oxo-pregn-4-ene-21, 17-carbolactones by the metal-free oxidation of 17-(3-hydroxypropyl)-3,17-dihydroxyandrostanes - Google Patents
Process for the production of 3-oxo-pregn-4-ene-21, 17-carbolactones by the metal-free oxidation of 17-(3-hydroxypropyl)-3,17-dihydroxyandrostanes Download PDFInfo
- Publication number
- US20070049747A1 US20070049747A1 US11/490,543 US49054306A US2007049747A1 US 20070049747 A1 US20070049747 A1 US 20070049747A1 US 49054306 A US49054306 A US 49054306A US 2007049747 A1 US2007049747 A1 US 2007049747A1
- Authority
- US
- United States
- Prior art keywords
- hydrogen
- group
- double bond
- formula
- process according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 *C1(*)C2C3[C@H]([15*])[C@H]([16*])C4(CCC(=O)O4)[C@@]3([13*])C[C@@H]([11*])[C@]2([9*])[C@@]2([10*])CCC(=O)C[C@@]2([5*])C1(*)* Chemical compound *C1(*)C2C3[C@H]([15*])[C@H]([16*])C4(CCC(=O)O4)[C@@]3([13*])C[C@@H]([11*])[C@]2([9*])[C@@]2([10*])CCC(=O)C[C@@]2([5*])C1(*)* 0.000 description 22
- ZDMZCRYKODGNBZ-ZNQSOWIESA-N C[C@]12CCC3C(C1[C@@H]1C[C@@H]1[C@@]2(O)CCCO)[C@H]1C[C@H]1[C@]1(O)C[C@@H](O)CC[C@]31C Chemical compound C[C@]12CCC3C(C1[C@@H]1C[C@@H]1[C@@]2(O)CCCO)[C@H]1C[C@H]1[C@]1(O)C[C@@H](O)CC[C@]31C ZDMZCRYKODGNBZ-ZNQSOWIESA-N 0.000 description 3
- RQANBDIXNMIXPA-MDCGLMOLSA-N C[C@]12CCC3C(C1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1)[C@H]1C[C@H]1[C@]1(O)CC(=O)CC[C@]31C Chemical compound C[C@]12CCC3C(C1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1)[C@H]1C[C@H]1[C@]1(O)CC(=O)CC[C@]31C RQANBDIXNMIXPA-MDCGLMOLSA-N 0.000 description 2
- NUSQUDGLOSMYJX-UHFFFAOYSA-N CC1CCC(O)(CCCO)C1(C)C.CC1CCC2(CCC(=O)O2)C1(C)C Chemical compound CC1CCC(O)(CCCO)C1(C)C.CC1CCC2(CCC(=O)O2)C1(C)C NUSQUDGLOSMYJX-UHFFFAOYSA-N 0.000 description 1
- DQIHKYQHGGDJGB-HQPACFAYSA-M C[C@]12CCC3C(C1[C@@H]1C[C@@H]1[C@@]2(O)CCCO)[C@H]1C[C@H]1[C@]1(O)C[C@@H](O)CC[C@]31C.C[C@]12CCC3C(C1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1)[C@H]1C[C@H]1C1=CC(=O)CC[C@@]13C.C[C@]12CCC3C(C1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1)[C@H]1C[C@H]1[C@]1(O)CC(=O)CC[C@]31C.C[C@]12CCC3C(C1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1)[C@H]1C[C@H]1[C@]1(O)CC(=O)CC[C@]31C.[V]I Chemical compound C[C@]12CCC3C(C1[C@@H]1C[C@@H]1[C@@]2(O)CCCO)[C@H]1C[C@H]1[C@]1(O)C[C@@H](O)CC[C@]31C.C[C@]12CCC3C(C1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1)[C@H]1C[C@H]1C1=CC(=O)CC[C@@]13C.C[C@]12CCC3C(C1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1)[C@H]1C[C@H]1[C@]1(O)CC(=O)CC[C@]31C.C[C@]12CCC3C(C1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1)[C@H]1C[C@H]1[C@]1(O)CC(=O)CC[C@]31C.[V]I DQIHKYQHGGDJGB-HQPACFAYSA-M 0.000 description 1
- METQSPRSQINEEU-GGORKCOASA-N C[C@]12CCC3C(C1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1)[C@H]1C[C@H]1C1=CC(=O)CC[C@@]13C Chemical compound C[C@]12CCC3C(C1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1)[C@H]1C[C@H]1C1=CC(=O)CC[C@@]13C METQSPRSQINEEU-GGORKCOASA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
- C07J53/002—Carbocyclic rings fused
- C07J53/004—3 membered carbocyclic rings
- C07J53/008—3 membered carbocyclic rings in position 15/16
Definitions
- This invention relates to processes for the production of 3-oxo-pregnane-21,17-carbo-lactones as well as 3-oxo-pregn4-ene-21,17-carbolactones, in particular processes for the production of 3-oxo-17 ⁇ -pregnane-21,17-carbolactones as well as 3-oxo-17 ⁇ -pregn4-ene-21,17-carbolactones.
- the invention relates to the dichloro-methane hemisolvate of 6 ⁇ ,7 ⁇ ;15 ⁇ ,16 ⁇ -dimethylene-3-oxo-17 ⁇ -pregnan-5 ⁇ -ol-21,17 carbolactone.
- Examples of pharmacologically active steroid-21,17-carbolactones are eplerenone (9 ⁇ ,11 ⁇ -epoxy-7 ⁇ -methoxycarbonyl-3-oxo-17 ⁇ -pregn-4-ene-21,17-carbolactone), drospirenone (6 ⁇ ,7 ⁇ ;15 ⁇ ,16 ⁇ -dimethylene-3-oxo-17 ⁇ -pregn-4-ene-21,17-carbolactone), spironolactone (7 ⁇ -acylthio-3-oxo-17 ⁇ -pregn-4-ene-21,17-carbolactone), canrenone (3-oxo-17 ⁇ -pregna-4,6-diene-21,17-carbolactone), and prorenone (6 ⁇ ,7 ⁇ -methylene-3-oxo-17 ⁇ -pregna-4,6-diene-21,17-carbolactone).
- the build-up of the steroid-21,17-spirolactone can be carried out by oxidation of the corresponding 17-hydroxy-17-(3-hydroxypropyl) steroid with suitable oxidizing agents such as chromic acid (Sam et al. J. Med. Chem. 1995, 38, 4518-4528), pyridinium chlorochromate (EP 075189), pyridinium dichromate (Bittler et al; Angew. Chem. [Applied Chem.] 1982, 94, 718-719; Nickisch et al. Liebigs Ann. Chem. 1988, 579-584), or potassium bromate in the presence of a ruthenium catalyst (EP 918791).
- suitable oxidizing agents such as chromic acid (Sam et al. J. Med. Chem. 1995, 38, 4518-4528), pyridinium chlorochromate (EP 075189), pyridinium dichromate (Bittler et al; Angew
- the object of this invention therefore consists in making available an alternate process for the production of 3-oxo-pregnane-21,17-carbolactones as well as 3-oxo-pregn-4-ene-21,17-carbolactones from the corresponding 17-(3-hydroxypropyl)-3,17-dihydroxy-androstanes that makes it possible to produce the target compounds with a higher yield and purity.
- R 5 is hydrogen, hydroxy
- R 6a is hydrogen, together with R 5 a double bond, or together with R 7a a —CH 2 group;
- R 6b is hydrogen, together with R 7b a —CH 2 group or a double bond;
- R 7a is hydrogen, C 1 -C 4 -alkyl, C 1 -C 4 -alkoxycarbonyl, C 1 -C 4 -thioacyl or together with R 6a a —CH 2 group;
- R 7b is hydrogen, or together with R 6b a —CH 2 group
- R 9 is hydrogen, together with R 11 a double bond, or together with R 11 an epoxy group -O-;
- R 10 is hydrogen, methyl, or ethyl
- R 11 is hydrogen, together with R 9 a double bond or together with R 9 an epoxy group -O-;
- R 13 is hydrogen, methyl or ethyl
- R 15 is hydrogen, C 1 -C 4 -alkyl, together with R 16 a —CH 2 group or a double bond,
- R 16 is hydrogen, together with R 15 a —CH 2 group or a double bond, are reacted with an organic or inorganic hypochlorite as an oxidizing agent in the presence of catalytic amounts of a 2,2,6,6-tetramethylpiperidine-N-oxide derivative to form the 3-oxo-pregnane-21,17-carbolactones of Formula II
- R 5 is a hydroxy group
- the compounds of formula II can be converted in the presence of an acid at pH ⁇ 5 with water being eliminated into compounds of formula III
- Primary alcohols can be oxidized to aldehydes with sodium bromite (NaBrO 2 ) or calcium hypochlorite [Ca(OCl 2 )] in the presence of TEMPO derivatives [S. Torii et al. J. Org. Chem. 1990, 55, 462-466].
- Sodium hypochlorite (NaOCl) can also be used as an oxidizing agent (Org. Synth. 69, 212).
- the oxidative lactonization of 1,4-diols proceeds in many stages via the aldehyde, which first forms lactol in an intermediate stage; the quasi-secondary hydroxy group of said lactol must then be further oxidized.
- the oxidative lactonization of 1,4-diols therefore requires still harder conditions (at least equimolar amounts of the TEMPO derivative (J. M. Bobbilt et al., J. Org. Chem. 1991, 56, 6110-6114) or other oxidizing agents in connection with increased amounts of the TEMPO catalyst (J. Einhorn, J. Org. Chem. 1996, 61, 7452-7454; in the presence of a bromide addition: S. D.
- the process according to the invention is performed with a total of at least 3 molar equivalents of alkali hypochlorite, organic hypochlorite or at least 1.5 molar equivalents of alkaline-earth hypochlorite as oxidizing agent; preferably with 3-6 molar equivalents of alkali hypochlorite, or 1.5-3 molar equivalents of alkaline-earth hypochlorite, especially preferably 3-4 molar equivalents of alkali hypochlorite or 1.5-2 molar equivalents of alkaline-earth hypochlorite, most preferably 3.0-3.5 molar equivalents of alkali hypochlorite on 1.5-1.75 molar equivalents of alkaline-earth hypochlorite.
- the concentration of the aqueous hypochlorite solution during the oxidation is preferably adjusted such that it is 0.8 to 1.1 mol of hypochlorite/kg.
- Sodium hypochlorite, potassium hypochlorite, calcium hypochlorite or tert-butyl hypochlorite are preferably used as oxidizing agents.
- TEMPO derivatives 2,2,6,6-tetramethylpiperidine-N-oxide derivatives
- the amount is preferably 1-5 mol %, especially preferably 1-1.5 mol %.
- Suitable TEMPO derivatives are, i.a., the 2,2,6,6-tetramethylpiperidine-N-oxide (TEMPO), the 4-methoxy-2,2,6,6-tetramethylpiperidine-N-oxide (4-MeO-TEMPO) as well as the 4-benzyloxy-2,2,6,6-tetramethylpiperidine-N-oxide (4-BnO-TEMPO).
- TEMPO is preferably used according to this invention, especially preferably in an amount of 1-5 mol %, quite especially preferably 1-1.5 mol %.
- the oxidation is carried out in an organic solvent or in a two-phase solvent-water mixture, whereby the solvent is selected such that both the TEMPO derivative and the compounds of formula I can be well dissolved therein.
- the reaction is preferably performed in a two-phase system.
- the process according to the invention is quite preferably performed in a dichloromethane-water mixture.
- the oxidation is performed according to the invention at a temperature of 0 to 20° C., e.g., 0 to 15° C., preferably at 10-20° C.
- the pH of the reaction solution is to be at least 8.0; preferably 8.5 to 10.0; especially preferably 9.0 to 9.5.
- the pH can suitably be adjusted with a suitable Brönsted acid, such as organic acids (e.g., acetic acid) or inorganic acids (HCl, H 2 SO 4 , H 3 PO 4 ) or acid salts of multivalent acids (bicarbonates, hydrogen sulfates, hydrogen phosphates, etc.).
- a suitable Brönsted acid such as organic acids (e.g., acetic acid) or inorganic acids (HCl, H 2 SO 4 , H 3 PO 4 ) or acid salts of multivalent acids (bicarbonates, hydrogen sulfates, hydrogen phosphates, etc.).
- Alkali bicarbonates especially preferably potassium bicarbonate
- the oxidation reaction is brought to a halt by adding a reducing agent to quench excess hypochlorite reagent.
- any reducing agent with corresponding redox potential that is known to one skilled in the art is suitable.
- An aqueous alkali hydrogen sulfite solution is preferably used according to
- the 3-oxo-pregnane-21,17-carbolactones of formula II (if R 5 ⁇ OH) thus eliminate water, and equally the 3-oxo-pregn-4-ene-21,17-carbolactones of formula III are formed in the reaction mixture.
- the completion of the oxidation reaction at a pH of less than 5 makes possible the production of compounds of formula III in a one-pot process.
- the excess hypochorite reagent is quenched with the addition of a base or a basic buffer at pH>5, the 3-oxo-pregnane-21,17-carbolactones of formula II can be isolated.
- the completion of the oxidation reaction at a pH of more than 5 makes possible the specific production of compounds of formula II.
- any suitable inorganic or organic base or any suitable buffer or any suitable buffer system can be used.
- the base or buffer is preferably added mixed or in parallel to the reaction mixture with the reducing agent.
- sodium phosphate (Na 3 PO 4 ) is preferably used as a basic buffer.
- 17-(3-Hydroxypropyl)-3,17-dihydroxyandrostanes of general formula I can be obtained, e.g., starting from the correspondingly substituted 3-hydroxy-17-ketoandrostanes by the addition of propargyl alcohol at C-17 and subsequent hydrogenation of the triple bond (EP 918791, EP 51143, DE 3026783) or as described by N. W. Atwater in J. Org. Chem. 1961, 26, 3077 and in U.S. Pat. No. 4,069,219 or in the documents cited therein.
- the corresponding 3-hydroxy-17-ketoandrostanes can be produced in turn from the correspondingly substituted 3-hydroxyandrost-5-en-17-one (EP 51143, DE 3026783).
- the process according to the invention is suitable especially for the production of 3-oxo-17 ⁇ -pregnane-21,17-carbolactones of formula IIa as well as 3-oxo-17 ⁇ -pregn-4-ene-21,17-carbolactones of formula IIIa, in which the substituents R have the following meaning:
- R 6a is hydrogen or together with R 7a a —CH 2 group
- R 6b is hydrogen, together with R 7b a —CH 2 group, or a double bond;
- R 7a is hydrogen, C 1 -C 4 -alkoxycarbonyl, or C 1 -C 4 -thioacyl
- R 7b is hydrogen, or together with R 6b a —CH 2 group
- R 9 is hydrogen, together with R 11 a double bond or together with R 11 an epoxy group -O-;
- R 10 is hydrogen, or methyl
- R 11 is hydrogen, together with R 9 a double bond or together with R 9 an epoxy group —O—;
- R 15 is hydrogen, together with R 16 a —CH 2 group or a double bond
- R 16 is hydrogen, together with R 15 a —CH 2 group or a double bond; whereby as starting materials, the 17-(3-hydroxypropyl)-3,17-dihydroxyandrostanes of general formula Ia are used.
- R 6a , R7a, R 9 , R 11 are hydrogen
- R 6b and R 7b together are a —CH 2 group
- R 10 is methyl
- R 15 and R 16 together are a —CH 2 group; thus compounds IIb as well as IIIb, whereby the compound of formula Ib is used as a starting material is quite especially suitable.
- Another aspect of this invention is the poorly soluble dichloromethane-hemisolvate IV that is formed, surprisingly enough, from compound IIb when the process according to the invention is performed in dichloromethane and is worked up, basic, at pH>5. During the oxidation, this poorly soluble product precipitates, and thus the influence of the oxidizing agent and thus possible further reactions, which can result in the formation of by-products, are evaded, thereby providing the hemisolvate IV in good purity.
- the dichloromethane-hemisolvate IV is distinguished by a strict and constant melting point, which is 121° C., while compound IIb melts at 188° C. DSC (Differential Scanning Calorimetry) measurements have shown that compound IV is stable up to the melting point.
- isolation or “isolated” and the like as used herein mean separation of the subject compound (e.g., that of the Formula II) at a pH>5 (preferably in the presence of methylene chloride) from the reaction solution in which it is prepared; or separation of the subject compound by crystallization and/or precipitation; or separation (e.g., substantially) from the non-polar oxidation or elimination products in the reaction solution in which the compound of Formula II is prepared; or separation from the reaction solution in a form whereby no more than 6% of steroidal contaminants are present in the resultant product (based on total weight therof).
- a pH>5 preferably in the presence of methylene chloride
- Ib can be oxidized to IIb and converted directly to IIIb in the same pot by the reaction mixture being worked up under acidic conditions at pH ⁇ 5.
- TABLE 1 Comparison of the Yields of the Process According to the Invention Compared to the Process of the Prior Art Yield (% of Theory) Process Ib ⁇ IIb IIb ⁇ IIIb Total (Ia ⁇ IIIb) Process According to 82 94 77 the Invention (in the form of IV) Ru-Catalyzed Oxidation 75 94 70 According to EP 918791 CrO 3 Oxidation not isolated not isolated 56 According to EP 075189* *See Table on page 7 EP 918791
- a compound of formula I 76.9 mmol of a compound of formula I is dissolved or suspended in 135 ml of dichloromethane.
- 0.15 g (1 mmol) of TEMPO is added to the mixture at 15®C.
- the addition of a solution that consists of 134 g of a 15.25% aqueous sodium hypochlorite solution (230.7 mmol) and 8.20 g (82 mmol) of potassium bicarbonate in 114 ml of water is carried out, whereby a pH-value of 9.1 is set.
- the excess oxidizing agent is quenched at 15° C.
- aqueous solution that consists of 12.5 g (76.5 mmol) of sodium phosphate and 10.6 g (55.8 mmol) of sodium disulfite (Na 2 S 2 O 5 ) and 121 ml of water.
- the product of formula II is isolated from the organic phase by being precipitated from the reaction solution by adding 240 ml of diisopropyl ether, continuing to be stirred for 3 hours at 25° C., being filtered off and dried.
- the product that is already partially precipitated during the reaction depending on solubility in dichloromethane can be dissolved again by adding dichloromethane, and the organic phase is separated and redistilled in diisopropyl ether.
- the product that is precipitated in this case is filtered off with 300 ml of water, washed and dried.
- a compound of formula I 76.9 mmol of a compound of formula I is dissolved or suspended in 135 ml of dichloromethane.
- 0.15 g (1 mmol) of TEMPO is added at 15° C. to the mixture.
- the addition of a solution that consists of 134 g of a 15.25% aqueous sodium hypochlorite solution (230.7 mmol) and 8.20 g (82 mmol) of potassium bicarbonate in 114 ml of water is carried out, whereby a pH-value of 9.1 is set.
- the excess oxidizing agent is quenched at 15° C. by adding an aqueous solution of 10.6 g (55.8 mmol) of sodium disulfite (Na 2 S 2 O 5 ) in 121 ml of water.
- the pH of the reaction solution is set at pH ⁇ 5 by adding dilute, aqueous sulfuric acid, and stirring is continued at room temperature until the reaction is complete.
- the isolation of the product of formula III is carried out analogously to the isolation of the compounds of formula II according to GOP1, whereby the neutral washed organic phase is redistilled on diisopropyl ether.
- the product that is precipitated in this case is filtered off, washed with 300 ml of water and dried.
- the isolation of the product of formula III is carried out by precipitation by means of the addition of 90 ml of water.
- the precipitated product is filtered off with water, washed neutral and dried.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
as well as 3-oxo-pregn-4-ene-21,17-carbolactones of formula III
by the metal-free oxidation of 17-(3-hydroxypropyl)-3,17-dihydroxyandrostanes of formula I
Description
- This invention relates to processes for the production of 3-oxo-pregnane-21,17-carbo-lactones as well as 3-oxo-pregn4-ene-21,17-carbolactones, in particular processes for the production of 3-oxo-17α-pregnane-21,17-carbolactones as well as 3-oxo-17α-pregn4-ene-21,17-carbolactones. In addition, the invention relates to the dichloro-methane hemisolvate of 6β,7β;15β,16β-dimethylene-3-oxo-17α-pregnan-5β-ol-21,17 carbolactone.
- Examples of pharmacologically active steroid-21,17-carbolactones are eplerenone (9α,11α-epoxy-7α-methoxycarbonyl-3-oxo-17α-pregn-4-ene-21,17-carbolactone), drospirenone (6β,7β;15β,16β-dimethylene-3-oxo-17α-pregn-4-ene-21,17-carbolactone), spironolactone (7α-acylthio-3-oxo-17α-pregn-4-ene-21,17-carbolactone), canrenone (3-oxo-17α-pregna-4,6-diene-21,17-carbolactone), and prorenone (6β,7β-methylene-3-oxo-17α-pregna-4,6-diene-21,17-carbolactone).
- The build-up of the steroid-21,17-spirolactone can be carried out by oxidation of the corresponding 17-hydroxy-17-(3-hydroxypropyl) steroid
with suitable oxidizing agents such as chromic acid (Sam et al. J. Med. Chem. 1995, 38, 4518-4528), pyridinium chlorochromate (EP 075189), pyridinium dichromate (Bittler et al; Angew. Chem. [Applied Chem.] 1982, 94, 718-719; Nickisch et al. Liebigs Ann. Chem. 1988, 579-584), or potassium bromate in the presence of a ruthenium catalyst (EP 918791). The clearly pronounced formation of by-products by a number of secondary reactions is disadvantageous in the oxidation process of the prior art with chromium(VI) derivatives, by which the isolation of the pure product is hampered and the yield is reduced. The by-product profile is improved namely by the ruthenium-catalyzed oxidation (EP 918791), and thus also the yield increases. The use of transition metals in the production of pharmaceutical active ingredients, however, is generally associated with the drawback that the removal of heavy metal traces is already connected with an elevated expense. Moreover, large amounts of heavy metal-containing wastes accumulate in the production, and said wastes can be removed only in an intensive and costly way. - The object of this invention therefore consists in making available an alternate process for the production of 3-oxo-pregnane-21,17-carbolactones as well as 3-oxo-pregn-4-ene-21,17-carbolactones from the corresponding 17-(3-hydroxypropyl)-3,17-dihydroxy-androstanes that makes it possible to produce the target compounds with a higher yield and purity.
-
- R5 is hydrogen, hydroxy;
- R6a is hydrogen, together with R5 a double bond, or together with R7a a —CH2 group;
- R6b is hydrogen, together with R7b a —CH2 group or a double bond;
- R7a is hydrogen, C1-C4-alkyl, C1-C4-alkoxycarbonyl, C1-C4-thioacyl or together with R6a a —CH2 group;
- R7b is hydrogen, or together with R6b a —CH2 group;
- R9 is hydrogen, together with R11 a double bond, or together with R11 an epoxy group -O-;
- R10 is hydrogen, methyl, or ethyl;
- R11 is hydrogen, together with R9 a double bond or together with R9 an epoxy group -O-;
- R13 is hydrogen, methyl or ethyl;
- R15 is hydrogen, C1-C4-alkyl, together with R16 a —CH2 group or a double bond,
-
-
- Metal-free oxidations of alcohols to the corresponding aldehydes, ketones, carboxylic acids, lactols, and lactones are collectively referred to in the survey article of W. Adam et al., Chem. Rev. 2001, 101, 3499-3548. Metal-free oxidations in the presence of 2,2,6,6-tetramehylpiperidine-N-oxide (TEMPO) are described by van Bekkum et al. in Synthesis 1996, 1153-1174.
- Primary alcohols can be oxidized to aldehydes with sodium bromite (NaBrO2) or calcium hypochlorite [Ca(OCl2)] in the presence of TEMPO derivatives [S. Torii et al. J. Org. Chem. 1990, 55, 462-466]. Sodium hypochlorite (NaOCl) can also be used as an oxidizing agent (Org. Synth. 69, 212).
- The oxidation of secondary alcohols to ketones and in particular the oxidation of primary alcohols to carboxylic acids (or with suitable diols to lactones) requires a co-catalyst (P. L. Anelli et al., J. Org. Chem. 1987, 52, 2559-2562). As a co-catalyst, a bromide (generally KBr or NaBr) is used. The addition of bromide ions can be useful even in the oxidation of primary alcohols to aldehydes (P. L. Anelli et al., J. Org. Chem. 1987, 52, 2559-2562).
- The danger of the formation of bromine-containing by-products under oxidative conditions is disadvantageous in the use of bromides as co-catalysts. This oxidation method is especially suitable for the oxidation of primary alcohols to the corresponding aldehydes.
- Without the addition of bromide, the TEMPO-catalyzed oxidation of secondary alcohols to the corresponding ketones requires higher excesses of hypochlorite [3-4 molar equivalents of Ca(OCl)2, thus 6-8 molar equivalents of OCl−; (S. Tori et al. J. Org. Chem. 1990, 55, 462-466)].
- The oxidative lactonization of 1,4-diols proceeds in many stages via the aldehyde, which first forms lactol in an intermediate stage; the quasi-secondary hydroxy group of said lactol must then be further oxidized. The oxidative lactonization of 1,4-diols therefore requires still harder conditions (at least equimolar amounts of the TEMPO derivative (J. M. Bobbilt et al., J. Org. Chem. 1991, 56, 6110-6114) or other oxidizing agents in connection with increased amounts of the TEMPO catalyst (J. Einhorn, J. Org. Chem. 1996, 61, 7452-7454; in the presence of a bromide addition: S. D. Rychnovsky, J. Org. Chem. 1999, 64, 310-312; in the presence of bromide ions produced in situ from the oxidizing agent sodium bromite: S. Torii, J. Org. Chem. 1990, 55, 462-466). In view of the prior art, it was therefore surprising that oxidative lactonization on the D-ring and the oxidation of the secondary 3-hydroxy group of the 17-(3-hydroxypropyl)-3,17-dihydroxyandrostanes of general formula I (altogether three oxidation stages) can be performed successfully at the same time under mild conditions in the presence of catalytic amounts of TEMPO derivatives. In addition, it was surprising that the process according to the invention can be performed with only 1.0 to 2.0 equivalents of hypochlorite per oxidation stage, thus altogether 3.0 to 6.0 molar equivalents of hypochlorite quite without the co-catalytic bromide additions.
- The process according to the invention is performed with a total of at least 3 molar equivalents of alkali hypochlorite, organic hypochlorite or at least 1.5 molar equivalents of alkaline-earth hypochlorite as oxidizing agent; preferably with 3-6 molar equivalents of alkali hypochlorite, or 1.5-3 molar equivalents of alkaline-earth hypochlorite, especially preferably 3-4 molar equivalents of alkali hypochlorite or 1.5-2 molar equivalents of alkaline-earth hypochlorite, most preferably 3.0-3.5 molar equivalents of alkali hypochlorite on 1.5-1.75 molar equivalents of alkaline-earth hypochlorite.
- The concentration of the aqueous hypochlorite solution during the oxidation is preferably adjusted such that it is 0.8 to 1.1 mol of hypochlorite/kg. Sodium hypochlorite, potassium hypochlorite, calcium hypochlorite or tert-butyl hypochlorite are preferably used as oxidizing agents.
- The 2,2,6,6-tetramethylpiperidine-N-oxide derivatives (TEMPO derivatives) are used in catalytic amounts, whereby the amount is preferably 1-5 mol %, especially preferably 1-1.5 mol %.
- Suitable TEMPO derivatives are, i.a., the 2,2,6,6-tetramethylpiperidine-N-oxide (TEMPO), the 4-methoxy-2,2,6,6-tetramethylpiperidine-N-oxide (4-MeO-TEMPO) as well as the 4-benzyloxy-2,2,6,6-tetramethylpiperidine-N-oxide (4-BnO-TEMPO). TEMPO is preferably used according to this invention, especially preferably in an amount of 1-5 mol %, quite especially preferably 1-1.5 mol %.
- The oxidation is carried out in an organic solvent or in a two-phase solvent-water mixture, whereby the solvent is selected such that both the TEMPO derivative and the compounds of formula I can be well dissolved therein.
- The reaction is preferably performed in a two-phase system. The process according to the invention is quite preferably performed in a dichloromethane-water mixture.
- The oxidation is performed according to the invention at a temperature of 0 to 20° C., e.g., 0 to 15° C., preferably at 10-20° C.
- During the oxidation, the pH of the reaction solution is to be at least 8.0; preferably 8.5 to 10.0; especially preferably 9.0 to 9.5.
- The pH can suitably be adjusted with a suitable Brönsted acid, such as organic acids (e.g., acetic acid) or inorganic acids (HCl, H2SO4, H3PO4) or acid salts of multivalent acids (bicarbonates, hydrogen sulfates, hydrogen phosphates, etc.). Alkali bicarbonates, especially preferably potassium bicarbonate, are preferably used. The oxidation reaction is brought to a halt by adding a reducing agent to quench excess hypochlorite reagent. For this purpose, any reducing agent with corresponding redox potential that is known to one skilled in the art is suitable. An aqueous alkali hydrogen sulfite solution is preferably used according to this invention. Sodium or potassium hydrogen sulfite (NaHSO3 or KHSO3), the aqueous solution of sodium or potassium disulfite (Na2SO2O5 or K2S2O5) is especially preferably used.
- If, in the reaction mixture, the excess hypochlonte reagent at pH<5 is quenched thus without the addition of a base or a basic buffer, or in the presence of a further acid addition, the 3-oxo-pregnane-21,17-carbolactones of formula II (if R5═OH) thus eliminate water, and equally the 3-oxo-pregn-4-ene-21,17-carbolactones of formula III are formed in the reaction mixture. The completion of the oxidation reaction at a pH of less than 5 makes possible the production of compounds of formula III in a one-pot process.
- If, in the reaction mixture, the excess hypochorite reagent is quenched with the addition of a base or a basic buffer at pH>5, the 3-oxo-pregnane-21,17-carbolactones of formula II can be isolated. The completion of the oxidation reaction at a pH of more than 5 makes possible the specific production of compounds of formula II.
- Since in the case R5═OH the solubility of the compounds of formula II in comparison to the compounds of formula III in organic solvents is lower, the specific isolation of the compounds of formula II as an intermediate on the path to compounds of formula III offers the special advantage of the possibility of a more effective purification (e.g., by crystallization). The purified intermediates can be reacted according to the methods that are known in the literature with a suitable acid (such as, e.g., sulfuric acid, hydrochloric acid, para-toluenesulfonic acid, etc.) to form compounds of formula III (EP 0918791), thus advantageously lessening impurities in such formula III compounds, especially when R5═OH.
- To adjust the pH, any suitable inorganic or organic base or any suitable buffer or any suitable buffer system can be used. The base or buffer is preferably added mixed or in parallel to the reaction mixture with the reducing agent.
- According to this invention, sodium phosphate (Na3PO4) is preferably used as a basic buffer.
- 17-(3-Hydroxypropyl)-3,17-dihydroxyandrostanes of general formula I can be obtained, e.g., starting from the correspondingly substituted 3-hydroxy-17-ketoandrostanes by the addition of propargyl alcohol at C-17 and subsequent hydrogenation of the triple bond (EP 918791, EP 51143, DE 3026783) or as described by N. W. Atwater in J. Org. Chem. 1961, 26, 3077 and in U.S. Pat. No. 4,069,219 or in the documents cited therein. The corresponding 3-hydroxy-17-ketoandrostanes can be produced in turn from the correspondingly substituted 3-hydroxyandrost-5-en-17-one (EP 51143, DE 3026783).
-
- R6a is hydrogen or together with R7a a —CH2 group;
- R6b is hydrogen, together with R7b a —CH2 group, or a double bond;
- R7a is hydrogen, C1-C4-alkoxycarbonyl, or C1-C4-thioacyl;
- R7b is hydrogen, or together with R6b a —CH2 group,
- R9 is hydrogen, together with R11 a double bond or together with R11 an epoxy group -O-;
- R10 is hydrogen, or methyl;
- R11 is hydrogen, together with R9 a double bond or together with R9 an epoxy group —O—;
- R15 is hydrogen, together with R16 a —CH2 group or a double bond;
-
- The process according to the invention for the production of compounds of formulas IIa and IIIa,
- in which
- R6a, R7a, R9, R11 are hydrogen;
- R6b and R7b together are a —CH2 group;
- R10 is methyl;
-
- Another aspect of this invention is the poorly soluble dichloromethane-hemisolvate IV that is formed, surprisingly enough, from compound IIb when the process according to the invention is performed in dichloromethane and is worked up, basic, at pH>5. During the oxidation, this poorly soluble product precipitates, and thus the influence of the oxidizing agent and thus possible further reactions, which can result in the formation of by-products, are evaded, thereby providing the hemisolvate IV in good purity.
- The dichloromethane-hemisolvate IV is distinguished by a strict and constant melting point, which is 121° C., while compound IIb melts at 188° C. DSC (Differential Scanning Calorimetry) measurements have shown that compound IV is stable up to the melting point.
- After the reaction is completed, the precipitation of compound IV from the reaction solution by adding a non-polar solvent, preferably an ether, especially preferably diisopropyl ether, is completed. The non-polar oxidation and elimination products that are produced with the oxidation remain largely dissolved in the ether-dichloromethane mixture, which makes possible an extremely slight isolation of the compound IV at a high purity.
- In this way, compound IV with a yield of 82% is obtained. The thus obtained product contains no more than 6% steroidal contaminants and can easily be reacted without further purification according to known methods with a suitable acid to form drospirenone IIIb (EP 918791). The synthesis variant that runs through the isolated compound IV offers the additional advantage of a considerably higher total yield at IIIb by a simpler and more effective purification in the final stage. The total yield at IIIb is 77%, around 7% higher than according to the Ru-catalyzed oxidation process and subsequent water elimination and even around 21% higher than according to the one-pot process according to EP 075189 (Tab. 1).
- The terms “isolation” or “isolated” and the like as used herein mean separation of the subject compound (e.g., that of the Formula II) at a pH>5 (preferably in the presence of methylene chloride) from the reaction solution in which it is prepared; or separation of the subject compound by crystallization and/or precipitation; or separation (e.g., substantially) from the non-polar oxidation or elimination products in the reaction solution in which the compound of Formula II is prepared; or separation from the reaction solution in a form whereby no more than 6% of steroidal contaminants are present in the resultant product (based on total weight therof).
- As an alternative, Ib can be oxidized to IIb and converted directly to IIIb in the same pot by the reaction mixture being worked up under acidic conditions at pH<5.
TABLE 1 Comparison of the Yields of the Process According to the Invention Compared to the Process of the Prior Art Yield (% of Theory) Process Ib → IIb IIb → IIIb Total (Ia→IIIb) Process According to 82 94 77 the Invention (in the form of IV) Ru-Catalyzed Oxidation 75 94 70 According to EP 918791 CrO3 Oxidation not isolated not isolated 56 According to EP 075189*
*See Table on page 7 EP 918791
- This invention is explained in more detail based on the examples below, without being limited thereto.
- 76.9 mmol of a compound of formula I is dissolved or suspended in 135 ml of dichloromethane. First, 0.15 g (1 mmol) of TEMPO is added to the mixture at 15®C. The addition of a solution that consists of 134 g of a 15.25% aqueous sodium hypochlorite solution (230.7 mmol) and 8.20 g (82 mmol) of potassium bicarbonate in 114 ml of water is carried out, whereby a pH-value of 9.1 is set. After the reaction is completed, the excess oxidizing agent is quenched at 15° C. by adding an aqueous solution that consists of 12.5 g (76.5 mmol) of sodium phosphate and 10.6 g (55.8 mmol) of sodium disulfite (Na2S2O5) and 121 ml of water.
- The product of formula II is isolated from the organic phase by being precipitated from the reaction solution by adding 240 ml of diisopropyl ether, continuing to be stirred for 3 hours at 25° C., being filtered off and dried. As an alternative, the product that is already partially precipitated during the reaction depending on solubility in dichloromethane can be dissolved again by adding dichloromethane, and the organic phase is separated and redistilled in diisopropyl ether. The product that is precipitated in this case is filtered off with 300 ml of water, washed and dried.
- 76.9 mmol of a compound of formula I is dissolved or suspended in 135 ml of dichloromethane. First, 0.15 g (1 mmol) of TEMPO is added at 15° C. to the mixture. The addition of a solution that consists of 134 g of a 15.25% aqueous sodium hypochlorite solution (230.7 mmol) and 8.20 g (82 mmol) of potassium bicarbonate in 114 ml of water is carried out, whereby a pH-value of 9.1 is set. After the reaction is completed, the excess oxidizing agent is quenched at 15° C. by adding an aqueous solution of 10.6 g (55.8 mmol) of sodium disulfite (Na2S2O5) in 121 ml of water.
- The pH of the reaction solution is set at pH<5 by adding dilute, aqueous sulfuric acid, and stirring is continued at room temperature until the reaction is complete.
- The isolation of the product of formula III is carried out analogously to the isolation of the compounds of formula II according to GOP1, whereby the neutral washed organic phase is redistilled on diisopropyl ether. The product that is precipitated in this case is filtered off, washed with 300 ml of water and dried.
- 0.1 mol of a compound of formula II in which R5═OH, obtained according to GOP1, is suspended in 65 ml of tetrahydrofuran or dioxane and acidified to a pH of 1 by adding 5 ml of 20% sulfuric acid. At room temperature, stirring of the reaction mixture is continued until dehydration is completed.
- The isolation of the product of formula III is carried out by precipitation by means of the addition of 90 ml of water. The precipitated product is filtered off with water, washed neutral and dried.
- According to GOP1, 30 g (0.0769 mol) of 17α-(3-hydroxypropyl)-6β,7β;15β,6β-dimethylene-androstane-3β,5β,17β-triol is reacted.
- During the reaction, the product 6β,7β;15β,16β-dimethylene-3-oxo-17α-pregnan-5β-ol-21,17-carbolactone accumulates in the form of its dichloromethane hemisolvate. After excess oxidizing agent is destroyed and after working-up according to GOP1, 27 g of 6β,7β;15β,16β-dimethylene-3-oxo-17α-pregnan-5β-ol-21,17-carbolactone-dichloromethane hemisolvate (0.0630 mol)=82% of theory is isolated.
- [α]D 20=−61° (c=1.0; CHCl3); melting point=121° C.;
- 1H-NMR (400 MHz, CDCl3): δ=0.52 (q J=5.5 Hz, 1H, 21 α-H [of the 15,16-methylene bridge]), 0.68-0.78 (m, 2H, 20-H [of the 6,7-methylene bridge]), 0.89-0.97 (m, 1H, 6-H), 0.93 (s, 3H, 19-H), 0.99 (s, 3H, 18-H), 1.19-1.52 (m, 7H), 1.54-1.85 (m, 6H), 1.92 (dd J=3.8 and 11.8 Hz, 1H, 14-H), 2.06-2.16 (m, 1H, 22-H), 2.17-2.27 (m, 1H, 2α-H), 2.32-2.69 (m, 5H), 2.96 (d J=15.6 Hz, 1H, 4α-H), 5.30 (s, 1H, CH2Cl2).
- 13C-NMR (400 MHz, CDCl3): δ=9.97 (CH2, C-21), 11.63 (CH2, C-20), 16.74 (CH, C-15), 16.79 (CH, C-7), 17.29 (CH3, C-19), 19.83 (CH3, C-18), 21.75 (CH2, C-11), 24.31 (CH, C-16), 24.76 (CH, C-6), 29.35 (CH2, C-23), 30.70 (CH2, C-22), 33.96 (CH, C-8), 34.47 (CH2, C-1), 36.26 (CH2, C-2), 37.31 (CH2, C-12), 40.25 (C, C-10), 41.81 (C, C-13), 47.59 (CH, C-9), 52.18 (CH, C-14), 53.44 (CH2Cl2), 53.48 (CH2, C-4), 75.57 (C, C-5), 96.24 (C, C-17), 176.63 (C, C-24), 210.56 (C, C-3). MS (El, 70eV) m/e=384 (M+); m/e=366 (M+-H2O); m/e=314 (M+-C4H6O); m/e=111 (C7C11O+); m/e=91 (C6H11O+); m/e=55 (C3H3O+); m/e=43 (C2H3O+).
- IR: ∂=3483 cm−1 (OH); ∂=1757 cm−1 (C═O, lactone); ∂=1708 cm−1 (C═O); ∂=1200 cm−1 (O—C═O); ∂=1011 cm−1 (C—O)
- According to GOP2, 30 g (0.0769 mol) of 17α-(3-hydroxypropyl)-6β,7β;15β,16β-dimethylene-androstane-3β,5β,17β-triol is reacted. After excess oxidizing agent is destroyed according to GOP2, the reaction mixture is acidified with 10% sulfuric acid solution to a pH of 1 and stirred for 30 minutes at 25° C. After working-up according to GOP2, 21.5 g of 6β,7β;15β,16β-dimethylene-3-oxo-17α-preg-4-ene-21,17-carbolactone (0.059 mol)=76.7% of theory is isolated.
- [α]D 22≈182° (c=0.5 CHCl3); melting point=201.3° C.; UV (MeOH): ε265=19,000; most important 1H-NMR data (CDCl3): δ=0.40-0.67 (m, 1H, cyclopropyl H), 1.01 (s, 3H, 18-H), 1.11 (s, 3H, 19-H), 6.04 (s, 1H, 4-H) (D. Bittler, H. Hofmeister, H. Laurent, K. Nickisch, R. Nickolson, K. Petzoldt, R. Wiechert; Angew. Chem. Int. Ed. Engl. 1982, 21, 696-697];
- MS (El, 70 eV) m/e=366 (M+); m/e=338 (M+—CO); m/e=351 (M+—CH3); significant fragments: m/e=111; m/e=136; m/e=199, m/e=217; m/e=242; m/e=255; m/e=268; m/e=293 [Interpretation: See W. Krause, G. Kuehne; Steroids 1982, 40, 81-90].
- According to GOP3, 30 g (70,25 mmol) of 6β,7β:15β,16β-dimethylene-3-oxo-17α-pregnane-5β-ol-21,17-carbolactone dichlormethane hemisolvat (from Example 1) is reacted to yield 24.30 g of drospirenone (yield: 94.5%).
- Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The preceding preferred specific embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.
- In the foregoing and in the examples, all temperatures are set forth uncorrected in degrees Celsius and, all parts and percentages are by weight, unless otherwise indicated.
- The entire disclosures of all applications, patents and publications, cited herein and of corresponding European application No. 05090214.7, filed Jul. 21, 2005 are incorporated by reference herein.
- The preceding examples can be repeated with similar success by substituting the generically or specifically described reactants and/or operating conditions of this invention for those used in the preceding examples.
- From the foregoing description, one skilled in the art can easily ascertain the essential characteristics of this invention and, without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions.
Claims (31)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/187,672 US8658788B2 (en) | 2005-07-21 | 2011-07-21 | Process for the production of 3-oxo-pregn-4-ene-21,17-carbolactones by the metal-free oxidation of 17-(3-hydroxypropyl)-3,17-dihydroxyandrostanes |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05090214.7A EP1746101B2 (en) | 2005-07-21 | 2005-07-21 | Process for the production of Oxo-pregn-4-en-21,17-carbolactonen by metal free oxidation of 17-(3-hydroxypropyl)-3,17-dihydroxyandrostanes |
EP05090214.7 | 2005-07-21 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/187,672 Continuation US8658788B2 (en) | 2005-07-21 | 2011-07-21 | Process for the production of 3-oxo-pregn-4-ene-21,17-carbolactones by the metal-free oxidation of 17-(3-hydroxypropyl)-3,17-dihydroxyandrostanes |
Publications (1)
Publication Number | Publication Date |
---|---|
US20070049747A1 true US20070049747A1 (en) | 2007-03-01 |
Family
ID=35744678
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/490,543 Abandoned US20070049747A1 (en) | 2005-07-21 | 2006-07-21 | Process for the production of 3-oxo-pregn-4-ene-21, 17-carbolactones by the metal-free oxidation of 17-(3-hydroxypropyl)-3,17-dihydroxyandrostanes |
US13/187,672 Active 2026-08-22 US8658788B2 (en) | 2005-07-21 | 2011-07-21 | Process for the production of 3-oxo-pregn-4-ene-21,17-carbolactones by the metal-free oxidation of 17-(3-hydroxypropyl)-3,17-dihydroxyandrostanes |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/187,672 Active 2026-08-22 US8658788B2 (en) | 2005-07-21 | 2011-07-21 | Process for the production of 3-oxo-pregn-4-ene-21,17-carbolactones by the metal-free oxidation of 17-(3-hydroxypropyl)-3,17-dihydroxyandrostanes |
Country Status (22)
Country | Link |
---|---|
US (2) | US20070049747A1 (en) |
EP (1) | EP1746101B2 (en) |
JP (2) | JP5345843B2 (en) |
CN (1) | CN101223186B (en) |
AR (1) | AR055993A1 (en) |
AT (1) | ATE403668T1 (en) |
CY (1) | CY1110411T1 (en) |
DE (1) | DE502005004948D1 (en) |
DK (1) | DK1746101T4 (en) |
DO (1) | DOP2006000172A (en) |
ES (1) | ES2311927T5 (en) |
GT (1) | GT200600321A (en) |
MY (1) | MY147795A (en) |
PE (2) | PE20070215A1 (en) |
PL (1) | PL1746101T5 (en) |
PT (1) | PT1746101E (en) |
SI (1) | SI1746101T2 (en) |
SV (1) | SV2007002621A (en) |
TW (1) | TWI392683B (en) |
UA (1) | UA100092C2 (en) |
UY (1) | UY29686A1 (en) |
ZA (1) | ZA200801674B (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100130455A1 (en) * | 2008-03-05 | 2010-05-27 | Klaus Nickisch | Bismethylene-17a carbolactones and related uses |
US20100137264A1 (en) * | 2008-11-25 | 2010-06-03 | Klaus Nickisch | Progestational 3-(6,6-ethylene-17b-hydroxy-3-oxo-17a-pregna-4-ene-17a-yl)propionic acid g-lactones |
US20100261896A1 (en) * | 2009-04-10 | 2010-10-14 | Klaus Nickisch | Methods for the preparation of drospirenone |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE502005004948D1 (en) * | 2005-07-21 | 2008-09-18 | Bayer Schering Pharma Ag | Process for the preparation of 3-oxo-pregn-4-ene-21,17-carbolactones by the metal-free oxidation of 17- (3-hydroxypropyl) -3,17-dihydroxyandrostanes |
DE102008026793A1 (en) * | 2008-06-02 | 2009-12-03 | Bayer Schering Pharma Aktiengesellschaft | C-ring-substituted pregn-4-ene-21,17-carbolactones, as well as pharmaceutical compositions containing them |
ES2432063T3 (en) | 2009-06-16 | 2013-11-29 | Crystal Pharma, S.A.U. | Procedure for obtaining 17-spirolactones in steroids |
CN101775057B (en) * | 2010-02-09 | 2014-07-16 | 浙江仙琚制药股份有限公司 | Method for preparing drospirenone and intermediate thereof |
CN101830959B (en) * | 2010-05-27 | 2012-07-18 | 杭州龙山化工有限公司 | Method for synthesizing drospirenone |
US11351122B1 (en) | 2010-07-28 | 2022-06-07 | Laboratorios Leon Farma Sa | Synthetic progestogens and pharmaceutical compositions comprising the same |
US10849857B2 (en) | 2010-07-28 | 2020-12-01 | Laboratorios Leon Farma Sa | Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same |
AR081670A1 (en) | 2010-06-29 | 2012-10-10 | Leon Farma Sa Lab | PHARMACEUTICAL COMPOSITION INCLUDING DROSPIRENONE AND ANTI-ECONCEPTIVE KIT |
WO2012107513A1 (en) | 2011-02-10 | 2012-08-16 | Crystal Pharma, S.A.U. | Process for obtaining drospirenone |
CN102746370A (en) * | 2011-04-22 | 2012-10-24 | 天津金耀集团有限公司 | Novel technology for oxosynthesis of pregnane 11-bit ketonic group |
DE202012013345U1 (en) * | 2012-01-13 | 2016-06-17 | Saint-Gobain Glass France | Spacers for insulating glazings |
CN102887934B (en) * | 2012-09-20 | 2015-05-27 | 杭州福斯特药业有限公司 | Preparation method of drospirenone |
HUE032858T2 (en) * | 2013-04-12 | 2017-11-28 | Ind Chimica Srl | Process for the preparation of drospirenone |
CN104163846A (en) * | 2013-05-17 | 2014-11-26 | 上海创诺制药有限公司 | Method for preparing drospirenone |
EP3080376A1 (en) | 2013-12-12 | 2016-10-19 | Saint-Gobain Glass France | Spacer for insulating glazing units, comprising extruded profiled seal |
CN105793510A (en) | 2013-12-12 | 2016-07-20 | 法国圣戈班玻璃厂 | Double glazing having improved sealing |
CN104788524B (en) * | 2014-01-16 | 2016-07-06 | 浙江仙居君业药业有限公司 | A kind of preparation method of 19-nor--4-androstene-3,17-diketone |
US10301868B2 (en) | 2014-06-27 | 2019-05-28 | Saint-Gobain Glass France | Insulated glazing comprising a spacer, and production method |
EP3161237B1 (en) | 2014-06-27 | 2018-07-25 | Saint-Gobain Glass France | Insulating glazing with spacer and production method of such a spacer as well as use of such a insulating glazing as glazing for a building |
DK3198101T3 (en) | 2014-09-25 | 2018-12-03 | Saint Gobain | Spacer for double glazing |
PL3265636T3 (en) | 2015-03-02 | 2022-07-04 | Saint-Gobain Glass France | Glass fibre reinforced spacer for insulating glazing, method for manufacturing the same and use of such a spacer in multiple glazing |
MY187233A (en) | 2015-06-23 | 2021-09-13 | Laboratorios Leon Farma Sa | Drospirenone-based contraceptive for a female patient affected with excess weight |
EP3108889A1 (en) | 2015-06-23 | 2016-12-28 | Philippe Perrin | Drospirenone-based contraceptive for a female patient affected with excess weight |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5569652A (en) * | 1989-05-16 | 1996-10-29 | Schering Aktiengesellschaft | Dihydrospirorenone as an antiandrogen |
US6121465A (en) * | 1996-08-12 | 2000-09-19 | Schering Aktiengesellschaft | Process for production drospirenone and intermediate products of the process |
US20040220158A1 (en) * | 2002-08-16 | 2004-11-04 | White Michael J. | 5-Androsten-3beta-ol steroid intermediates and processes for their preparation |
US7319154B2 (en) * | 2005-07-21 | 2008-01-15 | Bayer Schering Pharma Ag | Process for the production of 3-oxo-pregn-4-ene-21, 17-carbolactones by the metal free oxidation of 17-(3-hydroxypropyl)-3, 17-dihydroxyandrostanes |
US20080032147A1 (en) * | 2005-08-26 | 2008-02-07 | Thomas Neel | Medium density fibreboard |
US20080207575A1 (en) * | 2004-12-06 | 2008-08-28 | Francesca Costantino | Process For The Preparation Of Drospirenone |
US7585971B2 (en) * | 2004-03-01 | 2009-09-08 | Industriale Chimica S.R.L. | Process for the preparation of drospirenone |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4069219A (en) | 1976-12-27 | 1978-01-17 | G. D. Searle & Co. | 7ξ-(Alkoxycarbonyl)-6ξ-alkyl/halo-17-hydroxy-3-oxo-17α-pregn-4-ene-21-carboxylic acid γ-lactones and corresponding 21-carboxylic acids, their salts, and esters |
DE3026783C2 (en) | 1980-07-11 | 1982-07-29 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | Process for the preparation of 5β-hydroxy- δ → 6 → steroids |
DE3042136A1 (en) | 1980-11-03 | 1982-06-09 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | METHOD FOR PRODUCING 3 (BETA), 7 (BETA) -DIHYDROXY- (DELTA) (UP ARROW) 5 (UP ARROW) STEROIDS |
EP0075189B1 (en) | 1981-09-21 | 1985-08-28 | Schering Aktiengesellschaft | 3-beta,7-beta,15-alpha-trihydroxy-5-androsten-17-one, its 3,15-dipivalate, and its preparation |
US5106995A (en) | 1989-05-05 | 1992-04-21 | Isp Investments Inc. | Production of lactones from diols |
JP2005027184A (en) * | 2003-07-04 | 2005-01-27 | Seiko Epson Corp | High frequency composite component |
DE502005004948D1 (en) * | 2005-07-21 | 2008-09-18 | Bayer Schering Pharma Ag | Process for the preparation of 3-oxo-pregn-4-ene-21,17-carbolactones by the metal-free oxidation of 17- (3-hydroxypropyl) -3,17-dihydroxyandrostanes |
-
2005
- 2005-07-21 DE DE502005004948T patent/DE502005004948D1/en active Active
- 2005-07-21 PT PT05090214T patent/PT1746101E/en unknown
- 2005-07-21 SI SI200530441T patent/SI1746101T2/en unknown
- 2005-07-21 EP EP05090214.7A patent/EP1746101B2/en active Active
- 2005-07-21 ES ES05090214.7T patent/ES2311927T5/en active Active
- 2005-07-21 DK DK05090214.7T patent/DK1746101T4/en active
- 2005-07-21 AT AT05090214T patent/ATE403668T1/en active
- 2005-07-21 PL PL05090214T patent/PL1746101T5/en unknown
-
2006
- 2006-07-19 DO DO2006000172A patent/DOP2006000172A/en unknown
- 2006-07-20 SV SV2006002621A patent/SV2007002621A/en active IP Right Grant
- 2006-07-20 PE PE2006000875A patent/PE20070215A1/en active IP Right Grant
- 2006-07-20 UA UAA200802003A patent/UA100092C2/en unknown
- 2006-07-20 AR ARP060103115A patent/AR055993A1/en not_active Application Discontinuation
- 2006-07-20 TW TW095126463A patent/TWI392683B/en active
- 2006-07-20 JP JP2008521908A patent/JP5345843B2/en active Active
- 2006-07-20 CN CN2006800263528A patent/CN101223186B/en active Active
- 2006-07-20 MY MYPI20063479A patent/MY147795A/en unknown
- 2006-07-20 UY UY29686A patent/UY29686A1/en active IP Right Grant
- 2006-07-20 PE PE2009001215A patent/PE20131303A1/en active IP Right Grant
- 2006-07-20 GT GT200600321A patent/GT200600321A/en unknown
- 2006-07-21 US US11/490,543 patent/US20070049747A1/en not_active Abandoned
-
2008
- 2008-02-20 ZA ZA200801674A patent/ZA200801674B/en unknown
- 2008-11-06 CY CY20081101259T patent/CY1110411T1/en unknown
-
2011
- 2011-07-21 US US13/187,672 patent/US8658788B2/en active Active
-
2013
- 2013-06-12 JP JP2013123726A patent/JP2013177450A/en active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5569652A (en) * | 1989-05-16 | 1996-10-29 | Schering Aktiengesellschaft | Dihydrospirorenone as an antiandrogen |
US6121465A (en) * | 1996-08-12 | 2000-09-19 | Schering Aktiengesellschaft | Process for production drospirenone and intermediate products of the process |
US20040220158A1 (en) * | 2002-08-16 | 2004-11-04 | White Michael J. | 5-Androsten-3beta-ol steroid intermediates and processes for their preparation |
US7585971B2 (en) * | 2004-03-01 | 2009-09-08 | Industriale Chimica S.R.L. | Process for the preparation of drospirenone |
US20080207575A1 (en) * | 2004-12-06 | 2008-08-28 | Francesca Costantino | Process For The Preparation Of Drospirenone |
US7319154B2 (en) * | 2005-07-21 | 2008-01-15 | Bayer Schering Pharma Ag | Process for the production of 3-oxo-pregn-4-ene-21, 17-carbolactones by the metal free oxidation of 17-(3-hydroxypropyl)-3, 17-dihydroxyandrostanes |
US20080032147A1 (en) * | 2005-08-26 | 2008-02-07 | Thomas Neel | Medium density fibreboard |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100130455A1 (en) * | 2008-03-05 | 2010-05-27 | Klaus Nickisch | Bismethylene-17a carbolactones and related uses |
US7960368B2 (en) | 2008-03-05 | 2011-06-14 | Everstra, Inc. | Bismethylene-17A carbolactones and related uses |
US20100137264A1 (en) * | 2008-11-25 | 2010-06-03 | Klaus Nickisch | Progestational 3-(6,6-ethylene-17b-hydroxy-3-oxo-17a-pregna-4-ene-17a-yl)propionic acid g-lactones |
US8222237B2 (en) | 2008-11-25 | 2012-07-17 | Evestra, Inc. | Progestational 3-(6,6-ethylene-17B-hydroxy-3-oxo-17A-pregna-4-ene-17A-yl)propionic acid G-lactones |
US20100261896A1 (en) * | 2009-04-10 | 2010-10-14 | Klaus Nickisch | Methods for the preparation of drospirenone |
US8334375B2 (en) | 2009-04-10 | 2012-12-18 | Evestra, Inc. | Methods for the preparation of drospirenone |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8658788B2 (en) | Process for the production of 3-oxo-pregn-4-ene-21,17-carbolactones by the metal-free oxidation of 17-(3-hydroxypropyl)-3,17-dihydroxyandrostanes | |
US7319154B2 (en) | Process for the production of 3-oxo-pregn-4-ene-21, 17-carbolactones by the metal free oxidation of 17-(3-hydroxypropyl)-3, 17-dihydroxyandrostanes | |
US6933395B1 (en) | PROCESSING FOR PRODUCING OF DROSPIRENONE (6β, 7β, 15β, 16β-DIMETHYLENE-3-OXO-17α-PREGN-4-EN-21, 17-CARBOLACTONE, DRSP) AS WELL AS 7α-(3-HYDOXY-1-PROPLY)-6β, 7β; 15β, 16β-DIMETHYLENE-5β-ANDROSTANE-3β, 5,17β-TRIOL(ZK 92836) AND 6β, 7β; 15β, 16β-DIMETHYLENE-5β-HYDROXY | |
EP2527356B1 (en) | Process for the Production of 3-Oxo-pregn-4-ene-21,17-carbolactones by the Metal-Free Oxidation of 17-(3-Hydroxypropyl)-3,17-dihydroxyandrostanes | |
US20100063272A1 (en) | Method for producing steroid compound | |
EP2253641A2 (en) | A process for preparing drospirenone and intermediate thereof | |
EP2415778B1 (en) | Methods for the preparation of Drospirenone and intermediates thereof | |
AU2012202868A1 (en) | Process for the production of 3-oxo-pregn-4-ene-21,17-carbolactones by the metal-free oxidation of 17-(3-hydroxypropyl)-3,17-dihydroxyandrostanes | |
EP2170926B1 (en) | Process for the preparation of 17-(3-hydroxypropyl)-17-hydroxysteroids |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: SCHERING AG, GERMANY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SEILZ, CARSTEN;SEBA, HARTMUT;REEL/FRAME:018593/0905 Effective date: 20061107 |
|
AS | Assignment |
Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT, GERMANY Free format text: CHANGE OF NAME;ASSIGNOR:SCHERING AKTIENGESELLSCHAFT;REEL/FRAME:020110/0334 Effective date: 20061229 Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT,GERMANY Free format text: CHANGE OF NAME;ASSIGNOR:SCHERING AKTIENGESELLSCHAFT;REEL/FRAME:020110/0334 Effective date: 20061229 |
|
AS | Assignment |
Owner name: BAYER PHARMA AKTIENGESELLSCHAFT, GERMANY Free format text: CHANGE OF NAME;ASSIGNOR:BAYER SCHERING PHARMA AKTIENGESELLSCHAFT;REEL/FRAME:026579/0001 Effective date: 20110701 |
|
STCB | Information on status: application discontinuation |
Free format text: EXPRESSLY ABANDONED -- DURING EXAMINATION |